1 sareum holdings plc or the company financial results for six months ended 31 december 2006 aim sar specialist structure based drug discovery business is pleased to announce its month period highlights during july three fold increase in revenues 205 000 2005 361 plus an of 319 deferred revenue pre payments be recognised current year gross profit 372 115 loss 65 reduction on ordinary activities after taxation 208 602 novel compounds discovered cancer collaboration with institute research and technologies ltd progress made further house programmes collaborations signed roche genentech piramed repeat from almirall lundbeck post end patent applications filed johnson & dr tim mitchell ceo
